Overall outcomes among people with peripheral T-cell lymphoma (PTCL) remain poor. The investigation and targeting of PTCL have lagged behind other lymphomas due to their relatively low incidence and the almost complete absence of model systems.
Recent advances from our laboratory and others have identified targetable nodes within each of the most common PTCL subtypes. We are leading a collective effort that spans multiple institutions to further the translation of novel therapies currently under investigation in the clinic.
We have already established a set of model systems, including patient-derived xenografts of NK-T cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, hepatosplenic T-cell lymphoma, anaplastic large-cell lymphoma, and sezary syndrome. Several of these models are being passaged as cell lines through a collaboration with the Broad Institute Cancer Cell Line Factory.
We lead a Specialized Center of Research supported by the Leukemia and Lymphoma Society with colleagues at Memorial Sloan-Kettering Cancer Center and Weil Cornell Medical College that spans basic, translational, and clinical research, including an open trial targeting PI3 kinase.
Our research is supported by the generosity of the Sandra and George Schussel Family Fund.